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a  b  s  t  r  a  c  t
Given  the  huge  disparity  in  the  chance  of  survival  for  children  with  cancer  born  in low  income  countries
(LICs)  compared  with  those  in high  income  ones,  there  is  an  urgent  need  to  assist  those  striving  to  support,
palliate  and  offer  curative  treatment  in  resource  limited  settings.  International  twinning  partnershipseywords:
winning partnerships
hildhood cancer
ow  and high income countries
offer  the  opportunity  to  provide  advice,  expertise,  support  and  technology  transfer  from  established
paediatric  oncology  units  to  developing  ones  in  order  to  help  them  overcome  the  challenges  facing  them.
It  may  help  them  to  avoid  the  mistakes  made  over  the  last  50 years  during  which  childhood  cancer
survival  has  progressed  in  high  income  countries  from  little  expectation  of  cure  to  75–80%  long  term
survival.  Projects  must  be locally  driven  by  the  team  in  the LIC, but  volunteers  and funding  organisations
can  help  to make  progress  possible.  There  is  mutual  beneﬁt  for all concerned.
© 2013 The Authors. Published by Elsevier Ltd. 
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Table 1
Key steps in twinning.
As cancer emerges as a life-threatening risk
• Local recognition of a need to develop a service
• Strong local medical/nursing leadership
• Creation of a team/hospital unit
• Local community mobilisation (friends/parents)
•  Recruitment to the cause of hospital management/health
planners/health ministries
•  Then external support sought/advice/funding
Ribeiro et al. [5] reported that the strongest correlation with
survival from childhood cancer in the ﬁrst 10 countries supported
by the “My  Child Matters” Project was governmental health care
Table 2
Obstacles to be overcome in starting the treatment of young people with cancer.
• Individual family, community, national poverty
•  Other overwhelming health priorities (e.g. communicable diseases)
•  Other societal problems – natural and man-made
•  Lack of cancer incidence/survival data (cancer burden/survival)
• Lack of awareness of signs/symptoms/perceptions of incurability
•  Lack of access to diagnosis/treatmentJ. Hopkins et al. / Journal of Ca
ntroduction
One of the medical success stories of the last 50 years has been
he progressive improvement in survival for children with cancer,
rom little expectation of cure in 1960 to 75–80% long term survival
n 2003 [1,2]. At least that is the picture in high income countries
HICs). In low-middle income countries (LMICs), where 80% of chil-
ren actually live, survival is 30% at best and under 10% in most
ow income countries [3–5]. In 2008 Dr. Margaret Chan, Director
eneral of the World Health Organisation (WHO) stated “The rise
f cancer in less afﬂuent countries is an impending disaster.”
Despite an increasing international recognition of the threat
f non-communicable diseases, including cancer, to the health of
ations the plight of children who develop cancer is frequently
verlooked [3]. There are a number of reasons for this. Childhood
ancer represents under 2% of the world’s cancer burden [6] and
he pattern of malignancies is very different to that seen in adults.
here is a greater possibility of prevention, by reducing excess envi-
onmental exposures, (e.g. smoking, diet, alcohol, sun-exposure)
n adult cancer than in children. Although, as a result of a con-
erted global effort, under 5 year mortality rates (U5MR) have been
igniﬁcantly reduced over the last 15–20 years (from 12 to 6.9 mil-
ion in 2011) [7], most deaths in children continue to result from
ommunicable diseases (e.g. malaria, pneumonia, Tb, HIV, diar-
hoea, measles) with or without associated malnutrition [8–10]. In
any Sub Saharan African countries U5MR still exceeds 160/1000
ive births [5,7,11,12], with cancer estimated to account for only
.14/1000 deaths.
However eminently treatable tumours, such as Burkitt lym-
homa (aetiologically linked to EB virus, chronic malarial infection
nd malnutrition) predominate in Sub Saharan Africa, especially.
t is highly relevant to the development of health services that
0% and 32% of under 5 deaths worldwide occur in Africa and
sia respectively. As the global efforts to decrease communicable
isease begins to succeed, childhood cancer emerges as a more sig-
iﬁcant threat to lives especially where socio-economic conditions
re improving. This is a pattern observed in higher income countries
n the 1950s. With the absence of true population based cancer
egistries in most low-middle income countries the precise burden
f childhood cancer has to remain an estimate. Based on the data
here registries do exist, the rates range worldwide between 80
nd 150 cases/million children. On this calculation there would be
etween 160,000 and 200,000 new cases worldwide per year, with
0% of those occurring in LMICs [6,13]. The majority of these chil-
ren will die following; very late or mis-diagnosis, or even missed
iagnosis; inability to afford therapy, toxicity and co-existing dis-
ases and malnutrition. Deprived of any chance of cure, the majority
eceive little or no relief of symptoms, especially of pain.
All children, irrespective of where they live, really do deserve
etter from the global community. It should not be beyond the abil-
ty and vision of professionals, parents/families, governments and
GOs/charities to redress the current inequality of access to care
14]. Many childhood cancers are curable at an affordable cost even
n countries with only basic healthcare systems. Burkitt lymphoma
15,16], nephroblastoma [17,18] and retinoblastoma [19,20] are
ood examples and account for nearly 50% of tumours seen in many
ub Saharan countries. Acute lymphoblastic leukaemia, the com-
onest single malignancy seen in HICs, has an increasing incidence
n LMICs as socio-economic conditions improve, as was seen in the
K, Europe and USA in the 1950–1960s. Affordable essential inves-
igation and therapy needs to be developed to increase survival in
MICs [21,22].International twinning partnerships can provide a way  to effec-
ively transfer expertise, skills and knowledge acquired in the HICs
ver the last few decades to try to improve; speed and accuracy
f diagnosis, supportive care, delivery of therapy safely and to• Long term collaboration with a twinned centre
Source:  Eden [27].
provide good palliation for children in LICs where local doctors and
nurses are trying to help children with malignancies. The twinning
model was pioneered by the St Jude Children’s Research Hospital
(Memphis, USA) International Outreach Group [23,24] and by the
Milan-Monza Group from Italy [25]. World Child Cancer, an Inter-
national Charity, was created in 2007 to raise funds, create twinning
partnerships worldwide, and to attempt to emulate the successes
of those pioneers and to improve supportive, palliative and curative
care in more LIMC countries worldwide [26].
The concepts of twinning
Given this huge disparity in survival between children in HICs
compared with LICs the concept that the lessons learnt over the
last few decades in higher income countries might be able to assist
doctors and nurses facing the dilemma of what more they could
do for the children with leukaemia and solid tumours presenting
at their limited resourced hospitals. This has led to the creation
of twinning partnerships. Table 1 shows the key steps required to
establish such a partnership.
Inherent in successful twinning is the concept that it must be
locally led by a developing team in the resource limited country
if it is to be successful and sustainable. The solutions to the chal-
lenges (see Table 2) must come from the local team not dictated
from outside the country but two-way transfer of expertise, advice,
knowledge and skills can help to speed up progress and help to
avoid the pitfalls experienced in HICs over the last few decades.
Above all the plans must be locally affordable if they are to be sus-
tainable. There is immense mutual beneﬁt to be gained by exploring
what is “essential” in terms of investigation, supportive and pallia-
tive care, and curative treatment. Truly optimal care may take some
longer time to develop. In any twinning project, long term com-
mitment and mutual respect from both sides of the partnership is
crucial. The challenges/obstacles must all be addressed within the
context of any twinning programme.
Poverty•  Lack of supportive/palliative care
• Lack of trained/experienced staff
•  Lack of ability to retain trained staff
• Major infrastructural problems e.g. transport to hospital/home
e10 J. Hopkins et al. / Journal of Cancer P
Table  3
Trends in under 5 mortality 1990–2008 (rate/1000 live births).
Region Fall in deaths % reduction % of worldwide
U5MR
Africa 168–132 21% 51%
North Africa/mid-East 77–43 44% 5%
Sub-Saharan 184–144 22% 50%
Asia  87–54 38% 42%
South Asia 124–76 39% 32%
East  Asia/Paciﬁc 54–28 48% 9%
Latin America/Caribbean 52–23 56% 3%
Industrialised Countries 10–6 40% 1%
Least Developed Countries 179–129 28% 40%
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xpenditure per capita and the resulting numbers of doctors and
urses employed per 1000 population. In the absence of state fund-
ng the full costs of most investigations and treatment for cancer
all to the family. When this is combined with lost earnings when
 mother/older sister has to spend time in hospital with the child,
t is not surprising that there is a high rate of treatment refusal and
bandonment in LICs (up to 60%) [28–30]. Premature curtailment
f treatment can only be overcome if the cost to families, of drugs
26], transport to and from hospital [31] and household income dis-
uption are addressed [30]. The need to complete therapy must be
tressed/communicated well to families [29]. The inﬂuence of local
healers’ in offering cheaper ‘remedies’ cannot be over-emphasised
they will not cure the child) [32,33].
ther overwhelming priorities
Table 3 shows the progress made in reducing U5MR. 90% of all
nder 5 deaths occur in 42 low-middle income countries. Concerted
fforts to reduce deaths from communicable diseases have been
ade but over 40 countries show negligible progress in doing so.
urative care for children with cancer cannot at present be a priority
n those countries, but in all countries relief of symptoms surely
hould be a critical priority. Paradoxically in those countries where
here has been a signiﬁcant reduction of U5MR, cancer with all of
ts complexity is emerging rapidly as a signiﬁcant threat to the lives
f children.
Regrettably, reductions in governmental overseas aid donations
y many HICs may  slow progress in attempts to reduce the risks
o children of both communicable and non-communicable dis-
ases. Disasters, natural and man-made inevitably distract from
nd reduce focus on health concerns. It is no coincidence that those
ountries with the worst track-record in improving maternal and
hild health are those involved in civil war or political strife.
ancer registration
If you do not know the true population incidence, mortality and
urvival for any disease it is impossible to assess progress in disease
ontrol, and the burden that disease represents for a population.
egrettably a minority of countries worldwide have such popula-
ion based cancer registries. The best that can be currently achieved
s a reliable 100% ascertainment of data on a hospital basis using
eliable ward logs, spread-sheets and ultimately online registra-
ion.
wareness of signs and symptomsLack of awareness of the meaning of the signs and symptoms
f disease by patients, families and health care professions leads
o late diagnosis, misdiagnosis, or missed diagnosis altogether.olicy 1 (2013) e8– e19
The time from ﬁrst symptom onset until diagnosis and start of
treatment is termed ‘symptom interval’ which has been exten-
sively investigated in high income countries as a possible cause
of treatment failure. In high income countries the principal rea-
sons for long symptom intervals are due to professional and system
delays especially for bone and brain tumours [34,35]. In low income
countries there may  be considerable delays in parents recognising
the seriousness of symptoms and in being unable to access health
care. Inadequate training of staff at health clinic level may  lead to
either no or delayed referral of patients to secondary care [36,37].
Evidenced suggests that at secondary and tertiary care levels, clin-
ical signs are most often recognised quickly. Speedy presentation
does relate to tumour biology so that children with leukaemia for
example with ﬂorid multiple signs generally present much quicker
than those with solid tumours. Children with advanced stage dis-
ease are much more likely to be impossible to cure and difﬁcult to
palliate.
Lack of diagnostic ability/capacity
There are three key components which inﬂuence long term sur-
vival; access to diagnosis, access to treatment and effective therapy.
Good clinical practice and basic imaging and laboratory tests can
assist the diagnosis in most children without the very sophisti-
cated investigations available in HICs. However good pathological
conﬁrmation of tumour type is important and some degree of
technology/expertise transfer maybe crucial in the early stages of
service delivery [11,38–40]. Hospital therapeutic capacity has to
be increased when more patients present. Drug supplies of essen-
tial cytotoxic and supportive drugs has proven to be a major issue
despite all of the necessary 19 (generic and off patent) drugs to
treat all common childhood cancers being on the WHO  Essen-
tial Medicines List for childhood cancer [41,42]. Yet some of those
drugs are not consistently available and/or affordable in even the
156 countries who have signed up to the Essential List. Target
17 of Goal 8 of the Millennium Declaration stated “the need for
cooperation with pharmaceutical companies to provide access to
affordable essential drugs in developing countries” [43]. Most LICs
do not produce their own drugs so importation is essential. There
is an urgent need to address globally, the production, distribution
and safety of such generic, off patent drugs for worldwide usage
[44–46]. Nowhere is this truer than for palliative care and espe-
cially pain relief. All the essential drugs are approved by WHO
[47]. However there remains in many countries a stigma asso-
ciated with prescribing, dispensing and usage of opiates, based
often on false beliefs regarding addiction. Again a worldwide strat-
egy and concerted effort is required to overcome this hurdle
[46].
Effective therapy in HICs is often complex, delivered ideally
within randomised clinical trials and expensive. The aim is to cure
at least 80% of all cases and hopefully 100% within the foreseeable
future. The stage reached in these countries has taken 50 plus years
to achieve.
Modiﬁed, graduated intensity strategies have been recom-
mended for use in LICs so that once experience has been gained
with low intensity therapy and toxicity minimised then therapy,
if affordable, can be intensiﬁed [22]. Successful use of basic ther-
apy in individual countries has been well documented [15,16,18]
and the French African Paediatric Oncology Group have developed
successful collaborative multicountry studies using such strate-
gies for Burkitt lymphoma and Wilms  tumour especially [17,48].
Similarly major progress with survival has occurred in Central
and South America using collaborative protocols as part of twin-
ning partnerships with St Jude Research Hospital, Milan-Monza,
and Hamilton Ontario Canada [49]. A crucial component of the
J. Hopkins et al. / Journal of Cancer P
Table 4
Crucial elements of each partnership.
• Raising awareness/potential to cure
•  Increase speed and accuracy of diagnosis
•  Increase diagnostic/therapeutic capacity
• Reduction of treatment refusal/abandonment
•  Ensure supply of good quality/affordable medicines
• Develop locally affordable therapy
•  Focus on good supportive/palliative care
•  Registration of all patients
• Train and retain staff
•  Support families/create parent groups
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ollaborative groups, especially of the MISPHO programme has
een the regular educational focus for oncology nurses, support-
ve care, tumour speciﬁc updates, epidemiology and progressively
ancer research methodology [49].
The International Society of Paediatric Oncology PODC group
ave recently produced a series of Guidelines for the Management
f Children in low income settings for Wilms  tumour [50], Endemic
urkitt Lymphoma [51], Kaposi Sarcoma [52], Retinoblastoma [53]
nd Supportive Care [54]. A six country collaborative project to con-
ert the guidelines for Wilms  tumour into a speciﬁc study is being
ctivated. More guidelines for other tumours and the development
f other potential collaborative studies are being developed.
raining and retention of staff
Underpinning all aspects of care must be appropriate train-
ng and retention of staff if therapy is to be successful and safe.
n the past too many doctors and nurses were recruited away to
ICs for training and better paid posts. Their acquired new skills
ere consequently lost to their home country. In most twinning
rogrammes the majority of training for nurses and doctors is
rganised in country or loco-regionally, in the same continent. If
 doctor or nurse does go abroad for speciﬁc training it is crucial
hat there is a job for him/her to return to with a salary commensu-
ate with the greater expertise, knowledge and value to the home
ountry/hospital. In country training programmes should consist of
hort (3- to 7-day) intensive workshops for nurses and doctors. The
opics should be decided by the local team and visiting colleagues
rom HICs selected to ensure they have speciﬁc expertise in the sub-
ects to be covered. Careful liaison prior to such teaching is essential
o ensure that what is discussed can be achieved locally. All aspects
f care/patient management (diagnosis, supportive, palliative and
urative care) need to be included. Between such workshops on-
oing dialogue using; internet – conferencing (e.g.Cure4Kids –
ttp://www.cure4kids.org [55] and/or www.medicineafrica.com
56]), regular telephone conferencing/emails and multidisciplinary
eetings for patient review, are all very important.
hallenges – how to help with them?
All of the above challenges naturally lead to a need to include all
f the features shown in Table 4 within any twinning programme.
wareness
This must include raising awareness of the signs and symp-
oms of cancer in children for the public so that families seek
elp in a timely fashion for cardinal features. This can be achieved
y using poster campaigns targeted at health clinics, schools,
hurches, etc., wherever adults meet. The messages must be clear,
ocally acceptable (there does remain considerable stigma asso-
iated with cancer in many cultures) and repeated on a regularolicy 1 (2013) e8– e19 e11
basis [57]. The presence of particular signs and symptoms needs
to trigger a speedy seeking of medical help. Such campaigns can
be augmented with media campaigns using radio, TV, newspapers,
etc.
At the same time community health workers, nurses and doctors
need to be educated through not just posters but by publicity and
inclusion in training workshops/visits of team members from the
twinning programme wherever possible.
The focus of awareness needs to be on a speedy diagnosis which
can provide a chance of cure and more rapid relief of symptoms.
Parents/parent groups/survivors of cancer can play a crucial role in
such awareness campaigns. Public awareness of survivors increases
belief in curability.
Diagnosis
Speed of diagnosis should reduce the incidence of late stage dis-
ease and toxic deaths resulting from poor health and malnutrition
at time of presentation which is currently very common in LICs [58].
Accuracy of diagnosis can present a problem because of lack
of diagnostic imaging, laboratory investigation and a paucity of
trained pathologists and of the sophisticated diagnostic tests avail-
able in HICs. Use of “remote” tele-pathology can help to train/assist
trained pathologists (who often do not have expertise in childhood
cancers) to make more precise diagnosis (not just a “small round
cell tumour”). Building capacity and quality of diagnostic services
must be a core component of any twinning. Cameras on micro-
scopes, internet exchange of images, web-based conferencing and
technology transfer should/can be included wherever a need exists
[39].
Reduction of treatment refusal/abandonment
In many LICs treatment refusal/abandonment maybe as high as
60% [28,29,30,59]. An increased belief in curability should emerge
after adequate awareness raising. However the major causes of
untimely cessation of treatment do relate to the cost of therapy
(drugs, transport to and from the hospital and loss of earnings
within the family) and major family disruption where every family
member has a key role. In addition when a child starts to look and
feel better after preliminary therapy, families do stop treatment
because they feel their child is now ‘cured’. Failure to communi-
cate well about the need for a full course of treatment has been
cited as critical in this happening [29].
Since in most low incomes settings, there is a lack of a compre-
hensive health service ﬁnanced by the Government, costs fall on
families. In the short to medium term a degree of subsidy for drug
and travel costs can be met  from external aid grants made by the
Twinning Project Organisation but also by local non-governmental
organisations created within country [60]. In the long term all
involved need to work with national governments for sustaina-
bility.
There is also an urgent need to work internationally to reduce
the cost of off patent generic cytotoxic and supportive drugs
[21,24,29,43,45,46,61,62] and to ensure consistent production and
a worldwide distribution.
Production of effective and affordable therapy
The recognition that it is necessary to graduate the intensity
of therapy to minimise cost and toxicity but yet offer chance of
cure has been documented earlier. Some challenge the “ethics” of
having different therapy for different children but when the alter-
native is certain death most practitioners do prefer to use what
is tolerable. The concept of graduated intensity protocols enables
e ncer P
i
t
r
S
T
t
h
e
n
i
t
i
a
[
D
1
b
a
i
D
T
t
b
t
c
o
t
a
w
m
e
T
F
t
w
t
s
w
a
c
t
g
l
[
d
c
a
s
a
o
n
m
t
e
[12 J. Hopkins et al. / Journal of Ca
ncreasing intensity when patients are seen to tolerate level one
reatment. This is after all what led us to the current 75–80% cure
ates in high income countries.
upportive and palliative care
Palliation of symptoms should start when the patient presents.
he relieve of symptoms especially pain must be a fundamen-
al component of all cancer therapy. Where a patient (as often
appens in LICs) presents with very advanced disease, often co-
xisting medical conditions and malnutrition, curative care may
ot be possible. Such children deserve the very best palliation. It
s essential that all involved in caring for children in LMICs are
rained in palliative care (from medical school and nurse train-
ng onwards) and that as a global community we  strive to make
vailable all necessary essential drugs to achieve that worldwide
47].
ata registration
In the absence of total population cancer registries, a good
00% ascertainment hospital register must sufﬁce. Funding may
e required for computer equipment, training and the salary of
 data manager to work with the clinical team to run the reg-
stration. We  have encouraged the use of web database (POND
atabase – www.POND4kids.org) for World Child Cancer projects.
his was created by St. Jude Hospital and provides an ability
o share anonymised data with funders for progress reporting
ut also as a clinical network develops within each coun-
ry (e.g. Bangladesh, Ghana, Philippines [26]) or even between
ountries (AHOPCA [49]). Such registration enables assessment
f progress in reducing treatment, abandonment, late diagnosis,
oxic deaths and improving survival but also provides invalu-
ble evidence to health planners of the cancer burden at least
ithin the speciﬁc hospitals. With a developing network a
ore clear picture of countrywide childhood cancer burden can
merge.
raining/retention of staff
Clearly this must be at the heart of all twinning partnerships.
unding should be available for visits of a small number of doc-
ors/nurses from the HIC twinning partner hospital to hold training
orkshops with content proposed by the local team. It appears
o work best if there are speciﬁc sessions for nurses and doctors
eparately but with some common time as well [49,63,64]. Well
orked out long term training modules are ideal but in all cases
ny educational momentum established by workshops needs to be
omplemented by on-going regular emails. Skype calls and online
raining site usage such as Cure4kids [65]. These all can provide on-
oing advice, transfer of expertise and exposure to a wide range of
iterature and experience. This website is free to registered users
65].
Within a twinning programme doctors and nurses from HICs
onate their time and expertise voluntarily so that a huge amount
an be achieved with relatively low expenditure (travel and
ccommodation only). Clearly sometimes it is appropriate that
taff from the developing centre do spend time abroad. Prefer-
bly this should be for short speciﬁc educational/training needs
r to attend an international congress which includes a sig-
iﬁcant relevant educational component (e.g. the SIOP Annual
eeting). The focus must be on retention of staff within coun-
ry. Some scope for loco-regional training within continents is
merging and this reduces the risk of losing trainees to HICs
66,67].olicy 1 (2013) e8– e19
Supporting families
Support should be provided to either establish de novo par-
ent groups or help those already in existence to clearly help new
families through their child’s illness but their input to aware-
ness campaigns, reduction of treatment abandonment/refusal and
developing long term sustainability is crucial. Many parent groups
in LICs start initiatives to raise funding for aspects of the service
themselves.
Long term sustainability
Advocacy by the local team and the twinning partner to hospital,
community, NGO and governmental authorities is necessary from
the outset if long term sustainability in country is to be achieved.
Unlimited duration of external aid can demotivate countries from
developing independence ﬁnancially for critical medical services.
The twinning partnership should and does almost always provide
long tern friendship and mutual support between individual doc-
tors and nurses and hospitals in both the LICs and HICs where
projects are developed. Such linkage persists beyond the duration
of actual funding.
World child cancer twinning – a model?
Following the twinning model outlined above and adapting it
to the needs of each individual project, World Child Cancer cre-
ates twinning partnerships between hospitals in LMICs and HICs to
encompass all of the aspects which make a partnership successful.
World Child Cancer acts as the facilitator and project manager
for these partnerships and provides essential funding. Often for
healthcare professionals the desire and willingness to make a dif-
ference and use their skills to help inform others is there, but a
heavy workload and restrictive employment mean that it is difﬁ-
cult to organise an effective twinning partnership without the help
of an external organisation. World Child Cancer takes on a project
management role and ensures that funding is secured for all aspects
of the project. In this way the professionals who are keen to dedi-
cate their time and direct their skills are relieved of administrative
burden of managing a project.
World Child Cancer is fortunate to have recruited some of the
world’s leading child cancer units and paediatric oncology doctors
and nurses to work on its projects as volunteers. The time and
expertise that they donate to projects is at least equal in value to
the ﬁnancial aid that the charity contributes to projects (see Fig. 1).
Since 2007 the charity has facilitated nine twinning partnerships
(in Ghana, Malawi, Mozambique, Cameroon, Mexico, Colombia,
Paciﬁc Islands, The Philippines and Bangladesh).
Most projects are based in a tertiary teaching hospital in a
LMIC and twinned with one or two  hospitals in HIC’s. The char-
ity has recruited hospitals from UK, The Netherlands, USA, Canada,
Singapore and South Africa to act as partners to the units in the
resourced limited countries (see Table 5).
Project selection criteria
World Child Cancer works in locations where it is conﬁdent that
there is the basis for progressing a practical and realistic develop-
ment plan. There are several selection criteria for considering a new
project including:• Location – preferably in a country with stable governance, no civil
war and essentially is a place to which it is safe to send medical
volunteers.
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programme:
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LFig. 1. The three-way relationship in a World Child Cancer twinning partnership.
Health statistics – the country should have made signiﬁcant
advances in reducing the under-5 mortality rate over the last 10
years; it is often around this time that cancer begins to emerge
as a common cause of death in children.
Leadership – it is essential that there is a strong local project leader
in place, preferably a doctor working in the paediatric oncology
unit, who has beneﬁted from some specialist experience or train-
ing in paediatrics and ideally in paediatric oncology and is capable
(and willing) to run the project
Feasibility – the charity looks for realistic and achievable objec-
tives which focus on curing curable and palliating the incurable.
The local project leader is asked to submit a 5-year development
able 5
ocation of current operational world child cancer funded twinning partnerships.
Project location Twinning partner/s 
Africa
Cameroon
Cameroon Baptist Hospital
Convention
Tygerberg Children’s
Hospital/Stellenbosch University,
SOUTH AFRICA
Ghana
Korle  Bu Teaching Hospital, Accra
Royal Hospital for Sick Children,
Edinburgh, UK
Malawi
Queen  Elizabeth Central Hospital,
Blantyre
VU University Medical Centre,
Amsterdam, and Royal Victoria
Inﬁrmary, Newcastle, UK
Asia
Philippines
Southern Philippines Medical Centre,
Davao (Mindanao)
University Hospital, Singapore and St
Jude Children’s Research Hospital, US
Bangladesh
Bangabandhu Sheikh Mujib Medical
University, Dhaka
British Columbia University,
Vancouver, CANADA and University
College Hospital, London, UK
Latin  America
Colombia
Instituto Nacional de Cancerlogia,
Bogota
Boston Children’s
Hospital/Dana-Farber, Boston, US
Multi-Country Projects
AHOPCA – Central American
Paediatric Haematology–Oncology
Project
St Jude Children’s Research Hospital,
USA and POGO, Ontario, Canadaolicy 1 (2013) e8– e19 e13
plan (with the input of the twinning partner wherever possible
and a member of the Project Committee of World Child Cancer)
including measurable aims and objectives year on year.
• Accountability – there must be a willingness to be account-
able for the funding that the project receives. The charity
requires 6-monthly ﬁnancial and qualitative reports to assess the
impact against agreed outcomes and outputs and yearly quan-
titative reports on progress (for example numbers of patients
seen/trends, changes in levels of late stage disease, treatment
refusal/abandonment, toxic deaths, and survival).
• Sustainability – there must be the potential to develop long-term
sustainability after funding from World Child Cancer comes to an
end. This includes both the potential for increased government
funding and of raising funding through the local parent support
groups and other local non-governmental organisations.
• Scalability – the charity’s approach focuses on identifying a ter-
tiary hospital in a LMIC which, through support from a twinning
partnership, becomes a centre of excellence and then a hub of
a network of satellite centres, culminating in child cancer treat-
ment being accessible across a country or region. See Fig. 2.
Project development process
The process of identifying and selecting a project can take
between one to two  years and involves the input of the charity’s
Project Committee which is made up of experts in child cancer
treatment and care from HIC’s and LMIC’s (see Fig. 3).
Beneﬁts of twinning
Twinning is a two-way transfer of expertise and skills which has
beneﬁts for hospitals and healthcare professionals for both the HIC
and LMIC’s. It is clear that there are huge beneﬁts to the receiving
healthcare system in the LMIC through the twinning partnership• Most importantly, child cancer survival rates can be improved
and access to treatment increased.
Cases p.a. Start date Stage in development
150 2012 Stage 2 – development of twining
partnership and local expertise
220 2010 Stage 3 – development of centre of
excellence in Accra
260 2009 Stage 3 – development of centre of
excellence in Blantyre
250 2010 Stage 4 – development of network of
satellite centres across Mindanao
linked to Davao centre of excellence
400 2012 Stage 3 – development of centre of
excellence in Dhaka
300 2009 Stage 3 – development of centre of
excellence in Bogota
1000 2012 Stage 5 – development of network
across El Salvador, Nicaragua, Panama,
Dominican Republic, Costa Rica,
Honduras, Guatamala
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Naonal Diagnosis and Survival Rates
Funding Guidelines
Fully sustainable 
through local 
funding
WCC supplements 
gov funding with 
£100-200k p.a.
WCC supplements 
gov funding with 
£160-300k p.a.
Increased local 
funding. WCC 
funding tapers oﬀ to 
£100-200k p.a.
Limited gov funding
WCC £10-40k p.a.
WCC supplements 
gov funding with 
£100-200k p.a.
> 70% diagnosis
50-65% survival
> 50% diagnosis
40-50% survival
< 10% diagnosis
5-10% survival
< 20% diagnosis
10 -20% survival
> 30% diagnosis
10 -30% survival
> 40% diagnosis
25 -40% survival
Our Approach
5-10 Year Strategy
Each of our projects following a 5 -10 year 
strategy, depending on what stageof 
development they are at when 
World Child Cancer funding isagreed.
1 Idenfy
Idenﬁcaon of a 
hospital in low/ 
middle income 
country as Pilot Unit
2 Nurture
Create and nurture 
twinning partnership 
with hospital in high 
income country to 
create a two-way 
transfer of experse 
and skills
3 Develop
Develop pilot hospital 
into a Centre of 
Excellence through 
implementaon of 
training, data registry, 
awareness campaigns 
and parent support 
structure 
5 Scale
Scale the network of 
Satellite Centres to 
provide coverage 
naon-wide. A naonal 
strategic plan begins to 
evolve including 
increased government 
funding in capacity 
building
4 Expand
Expand access to 
treatment across the 
region through the 
creaon of shared 
care, between the 
Centre of Excellence 
and Satellite Centres
6 Exit
Once naonal 
coverage is achieved 
with full government 
support of child 
cancer as a naonal 
health priority, 
funding is ceased with 
connued mentoring 
through the twinning 
partnership
Fig. 2. Our approach 5–10 year strategy each of our projects following a 5–10 year strategy, depending on what stage of development they are at when World Child Cancer
f
•
•unding is agreed.
Healthcare professionals in LMIC’s gain specialist training from
knowledgeable and experienced healthcare professionals at no
cost or detriment to their own system.
Locally appropriate treatment protocols are developed and
implemented.
Fig. 3. Model for project development process.• The collection of statistical data is improved allowing an overview
of the problem in the country to be clearly understood for the ﬁrst
time.
• Volunteers often bring donated equipment for the
developing unit, and knowledge of how to use that
equipment.
• Extra funding is provided to fund staff posts, (for example data
managers, nurse salary supplementation for increased respon-
sibility to assist retention of key staff), improve facilities and
purchase drugs. Funding should be time limited for staff in order
to create local sustainability.
• Guidance is offered to the local support groups.
• Knowledge of other healthcare systems is gained and long-lasting
friendships developed.
The beneﬁts to hospitals and volunteers from HIC’s are less well
understood but are still signiﬁcant:
• Volunteers learn to work in very different environments from
the ones they are used to encouraging problem solving skills and
creativity.
• They become educated in the use of locally appro-
priate techniques and treating children with very few
resources.
• New research opportunities are possible by mutual agreement
between the two  units – academic ownership must lie with the
developing unit team.
• Volunteers develop an improved knowledge of global
health.
• Their assumptions are challenged and they gain an increased cul-
tural understanding and career commitment.• There are learning opportunities for CPD.
• And ﬁnally, as for LMIC healthcare professionals, long-lasting
friendships are made, both professionally and personally (see
Fig. 4).
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World Child Cancer currently has seven operational twinning
artnerships. Case studies from the projects in Malawi and The
hilippines are outlined below to show the impact that a twinning
artnership can have on diagnosis, treatment and care.
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Twinning partnerships are highly effective at transferring the
kills and expertise to try to improve diagnosis, treatment and care
or children with cancer in LMIC’s. Healthcare professionals from
oth HIC’s and LMIC’s can beneﬁt from the experience. Signiﬁcantly,
t is possible to scale-up a twinning project to encompass a region
f a country or a whole country.
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